Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-25 @ 2:02 AM
NCT ID:
NCT00941460
Eligibility Criteria:
Inclusion Criteria:
* Progressive or recurrent glioblastoma documented by MRI no earlier than 180 days after first surgery for glioblastoma and no earlier than 90 days after completion of radiotherapy.
* Histological diagnosis of glioblastoma
* Tissue available for the determination of MGMT promoter methylation in the primary tumor or from the recurrent tumor if a patient undergoes a surgical procedure at recurrence prior to study entry.
* Prior treatment with temozolomide administered concomitantly with radiotherapy and at least for two cycles (5/28) as an adjuvant treatment
* Informed consent
* Age 18-80 years
* Karnofsky performance score \> 50%
* Neutrophil counts \> 1 500/µl
* Platelet counts \> 100 000/µl
* Hemoglobin \> 10 g/dl
* Serum creatinin \< 1.5-fold upper normal range
* ASAT or ALAT \< 3-fold upper normal range unless attributed to anticonvulsants
* Alkaline phosphatase \< 3-fold upper normal range
* Women with childbearing potential must have a negative serum pregnancy test ≤14 days prior to study enrollment
* Willingness to apply contraception according to local requirements (as stated in patient information)
Exclusion Criteria:
* Progressive or recurrent glioblastoma documented by MRI earlier than 180 days after first surgery for glioblastoma and earlier than 90 days after completion of radiotherapy.
* Treatment with any chemotherapy other than temozolomide according to the schedule of the EORTC NCIC trial (Stupp et al. N Engl J Med 2005;352:987-996) except that an adjuvant starting dose of 200 mg/m2 and more than 6 cycles of adjuvant temozolomide are allowed
* Prior systemic or local treatment with DNA-damaging agents, tyrosine kinase inhibitors or anti-angiogenic agents for any cancer
* Allergy to or other intolerability of temozolomide
* Unable to undergo MRI
* Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation
* HIV infection
* Pregnancy
* Breast feeding
* Treatment within in any other clinical trial parallel to the treatment phase of the current study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT00941460
Study Brief:
Protocol Section:
NCT00941460